Medtronic announces ce mark of evolut™ pro+ tavi system for treatment of symptomatic severe aortic stenosis patients in europe

As tavi patient population grows, pro+ tavi system launches with four valve sizes and lowest delivery profile dublin, may 3, 2021 /prnewswire/ -- medtronic plc (nyse: mdt), the global leader in medical technology, today announced ce (conformitÉ europÉenne) mark of the evolut™ pro+ tavi system – the newest-generation medtronic tavi system that builds off the proven self-expanding, supra-annular evolut tavi platform. the evolut pro+ tavi system includes four valve sizes with an external pericardial tissue wrap that provides advanced sealing for the largest annular range (for self-expanding tavi technology) on the market.
MDT Ratings Summary
MDT Quant Ranking